|
|
Vaccine Detail
|
IFN/tremem |
| Vaccine Information |
- Vaccine Name: IFN/tremem
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007620
- Type: peptide vaccination
- Status: Research
- Antigen: IFN-α2b and tremelimumab (Tarhini et al., 2012)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: significant increase in the percentage of circulating T-reg, a significant decrease in the percentage of all MDSC populations tested at day 29, most significantly for the monocyte gate MDSC (HLA-DR+low/CD14+), decrease in the percentage of the lymphoid gate MDSC phenotype and in the percentage of the monocyte gate MDSC (Tarhini et al., 2012)
|
| References |
Tarhini et al., 2012: Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2012; 35(9); 702-710. [PubMed: 23090079].
|
|
